INDRAPRASTHA MEDICAL CORP Latest Share Price (INDRAMEDCO)
TODAY IN ONE LINE
INDRAMEDCO fell 1.4% on average volume, lagging Nifty's -0.3% move.
With a market cap of ₹3,245.68 Cr., it trades at a P/E of 17.26. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
INDRAPRASTHA MEDICAL CORP flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 11.3% and Profit up 33.9%
- ●High Capital EfficiencyROCE of 26.0% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 24.8%
- ●Healthy Operating MarginsOPM is structurally strong at 17.0%
- ●Steady Dividend YieldReliable 1.27% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Promoter SellingPromoter holding decreased by 1.61% QoQ
- ●Rising Receivables vs SalesReceivables grew 32.2% outpacing sales growth of 9.0%
Latest INDRAPRASTHA MEDICAL CORP News
What changed recently?
Recent events, corporate actions, and announcements.
INDRAPRASTHA MEDICAL CORP valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for INDRAPRASTHA MEDICAL CORP, framed against the sector median so the premium or discount is obvious at a glance.
INDRAPRASTHA MEDICAL CORP trades at a P/E of 17.26× and P/B of 4.38×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
INDRAPRASTHA MEDICAL CORP technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for INDRAPRASTHA MEDICAL CORP — derived from the latest tape, not yesterday's close.
INDRAPRASTHA MEDICAL CORP last traded at ₹355 with an intraday range of ₹344.1–₹356.2 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹355.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 383.63 | +28.63 | +8.07% |
| R3 | 371.53 | +16.53 | +4.66% |
| R2 | 363.87 | +8.87 | +2.50% |
| R1 | 359.43 | +4.43 | +1.25% |
| PIVOT | 351.77 | -3.23 | -0.91% |
| CURRENT | 355.00 | — | — |
| S1 | 347.33 | -7.67 | -2.16% |
| S2 | 339.67 | -15.33 | -4.32% |
| S3 | 335.23 | -19.77 | -5.57% |
| S4 | 323.13 | -31.87 | -8.98% |
INDRAMEDCO is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹344.1–₹355.5
Trading Below opening range, showing Bearishness
INDRAPRASTHA MEDICAL CORP financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for INDRAPRASTHA MEDICAL CORP — consolidated or standalone — with margins, YoY growth and key ratios inline.
INDRAPRASTHA MEDICAL CORP reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹3,245.68 Cr. and reported EPS of ₹6.09.
INDRAPRASTHA MEDICAL CORP segment analysis : revenue and profit mix.
Disclosed business segments at INDRAPRASTHA MEDICAL CORP with their share of revenue and profit, switchable between consolidated and standalone reporting.
INDRAPRASTHA MEDICAL CORP discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for INDRAPRASTHA MEDICAL CORP.
Our AI distills the core fundamental drivers supporting INDRAPRASTHA MEDICAL CORP, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
INDRAPRASTHA MEDICAL CORP's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 22 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 20% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.64%.
INDRAPRASTHA MEDICAL CORP peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — INDRAPRASTHA MEDICAL CORP is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
INDRAPRASTHA MEDICAL CORP chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for INDRAPRASTHA MEDICAL CORP — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
INDRAPRASTHA MEDICAL CORP delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for INDRAPRASTHA MEDICAL CORP over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in INDRAPRASTHA MEDICAL CORP stood at 63.5% of traded volume, against a 20-day average of 56.4%.
INDRAPRASTHA MEDICAL CORP announcements: results, concalls, ratings, M&A.
Filings INDRAPRASTHA MEDICAL CORP sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
INDRAPRASTHA MEDICAL CORP files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 68 documents below.
Copy of Newspaper Publication
Indraprastha Medical Corporation Limited has informed the Exchange about Copy of Newspaper Publication
Shareholders meeting
Indraprastha Medical Corporation Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2026
Record Date
Indraprastha Medical Corporation Limited has informed the Exchange that Record date for the purpose of Dividend is 18-Sep-2026.
General Updates
Indraprastha Medical Corporation Limited has informed the Exchange about General Updates
Copy of Newspaper Publication
Indraprastha Medical Corporation Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
INDRAPRASTHA MEDICAL CORP dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue INDRAPRASTHA MEDICAL CORP has declared, sequenced by announce and record date.
INDRAPRASTHA MEDICAL CORP corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About INDRAPRASTHA MEDICAL CORP: business, sector, key facts.
What INDRAPRASTHA MEDICAL CORP does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
INDRAPRASTHA MEDICAL CORP operates in the Hospital industry under the Healthcare sector, listed as NSE: INDRAMEDCO, BSE: 532150.
Indraprastha Medical Corporation Limited (INDRAMEDCO) is a prominent healthcare provider in India, operating a multi-specialty hospital in New Delhi. Their business model centers around delivering a wide range of medical services under one roof, catering to diverse patient needs and offering comprehensive care.
The hospital's services span numerous medical specialties, reflecting a commitment to holistic patient care. These include core areas like general surgery (including laparoscopic and robotic procedures), cardiology, oncology, and orthopedics. They also offer specialized services in high-demand areas such as bariatric and metabolic surgery, bone marrow transplant, IVF (in-vitro fertilization), and transplant services in general. Further strengthening their comprehensive approach are offerings in areas like endocrinology, gastroenterology, neurology, and psychiatry.
Beyond surgical and specialist care, INDRAMEDCO provides extensive diagnostic and support services. These encompass laboratory services, radiology and radio diagnosis, and advanced imaging techniques like nuclear medicine. The hospital also has dedicated departments for anesthesiology, critical care, emergency medicine, and rehabilitation, ensuring complete patient management from diagnosis to recovery. Preventive health services and specialized care for geriatric patients (elder care) further enhance their service portfolio.
The breadth of services offered demonstrates INDRAMEDCO's strategy to be a one-stop healthcare destination. This minimizes the need for patients to seek care from multiple providers, improving efficiency and convenience. The incorporation of advanced technologies, such as robotic surgery and hyperbaric oxygen therapy, showcases a commitment to adopting modern medical practices and providing high-quality treatment.
Established in 1983, INDRAMEDCO has a long history of serving the healthcare needs of the New Delhi region. Their extensive service offering and commitment to various medical specialties position them as a significant player in the Indian healthcare landscape, focusing on providing comprehensive and advanced medical care.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- DR AGARWALS HEALTH CARE L (AGARWALEYE) Share PricePeer
- APOLLO HOSPITALS ENTER L (APOLLOHOSP) Share PricePeer
- ARTEMIS MED SERVICE (ARTEMISMED) Share PricePeer
- ASTER DM QUALITY CARE (ASTERDM) Share PricePeer
- FORTIS HEALTHCARE (FORTIS) Share PricePeer
- Stocks near 52-week low (reversal watch)Screener
- Reversal Hunter strategy playbookStrategy
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about INDRAPRASTHA MEDICAL CORP (INDRAMEDCO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of INDRAPRASTHA MEDICAL CORP (INDRAMEDCO)?
The current share price of INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) is ₹355.00. Today, the stock has declined by ₹5.00 (1.39%), trading in a range of ₹344.10 to ₹356.20. The stock opened at ₹345.00 with a trading volume of 1,85,246 shares.
02Is INDRAPRASTHA MEDICAL CORP stock a good investment for long-term?
INDRAPRASTHA MEDICAL CORP can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,245.68 Cr., P/E ratio of 17.26, ROE of 24.8%, and ROCE of 25.98%. The dividend yield stands at 1.27%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of INDRAPRASTHA MEDICAL CORP stock?
The 52-week high price of INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) is ₹640.85, while the 52-week low is ₹342.00. Currently trading at ₹355.00, the stock is 3.8% above its 52-week low and 44.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy INDRAPRASTHA MEDICAL CORP stock at the current price?
Whether to buy INDRAPRASTHA MEDICAL CORP stock at ₹355.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 17.26 and P/B ratio of 4.38. Today's performance shows a loss of 1.39%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of INDRAPRASTHA MEDICAL CORP and when is the next dividend?
INDRAPRASTHA MEDICAL CORP offers a dividend yield of 1.27%, which means for every ₹100 invested at the current price of ₹355.00, you can expect to receive approximately ₹1.27 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of INDRAPRASTHA MEDICAL CORP?
INDRAPRASTHA MEDICAL CORP's key financial metrics include: P/E Ratio: 17.26, P/B Ratio: 4.38, ROE: 24.8%, ROCE: 25.98%, Dividend Yield: 1.27%, EPS: ₹6.09, Book Value: ₹80.76, and Debt-to-Equity: 0. The company's market cap stands at ₹3,245.68 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is INDRAPRASTHA MEDICAL CORP stock performing today in the market?
INDRAPRASTHA MEDICAL CORP stock opened at ₹345.00 and is currently trading at ₹355.00, showing a decline of ₹5.00 (1.39%). The intraday high is ₹356.20 and low is ₹344.10. The trading volume stands at 1,85,246 shares, indicating moderate market participation today.
08What is the P/E ratio of INDRAPRASTHA MEDICAL CORP and what does it indicate?
INDRAPRASTHA MEDICAL CORP has a Price-to-Earnings (P/E) ratio of 17.26, which means investors are willing to pay 17.26 for every ₹1 of earnings. With an EPS of ₹6.09, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.